114 related articles for article (PubMed ID: 20933412)
21. Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.
Isabel E; Powell DA; Black WC; Chan CC; Crane S; Gordon R; Guay J; Guiral S; Huang Z; Robichaud J; Skorey K; Tawa P; Xu L; Zhang L; Oballa R
Bioorg Med Chem Lett; 2011 Jan; 21(1):479-83. PubMed ID: 21074991
[TBL] [Abstract][Full Text] [Related]
22. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Yang SM; Tang Y; Zhang R; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6773-6. PubMed ID: 24153205
[TBL] [Abstract][Full Text] [Related]
23. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
24. Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.
Powell DA; Black WC; Bleasby K; Chan CC; Deschenes D; Gagnon M; Gordon R; Guay J; Guiral S; Hafey MJ; Huang Z; Isabel E; Leblanc Y; Styhler A; Xu LJ; Zhang L; Oballa RM
Bioorg Med Chem Lett; 2011 Dec; 21(24):7281-6. PubMed ID: 22047692
[TBL] [Abstract][Full Text] [Related]
25. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
Dobrzyn A; Ntambi JM
Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
[TBL] [Abstract][Full Text] [Related]
26. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
27. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
28. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
29. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
[TBL] [Abstract][Full Text] [Related]
30. Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Koltun DO; Zilbershtein TM; Migulin VA; Vasilevich NI; Parkhill EQ; Glushkov AI; McGregor MJ; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4070-4. PubMed ID: 19577469
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Takagi T; Wakimoto S; Ohsumi J
Eur J Med Chem; 2011 May; 46(5):1892-6. PubMed ID: 21356569
[TBL] [Abstract][Full Text] [Related]
32. Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
Uto Y; Ogata T; Harada J; Kiyotsuka Y; Ueno Y; Miyazawa Y; Kurata H; Deguchi T; Watanabe N; Takagi T; Wakimoto S; Okuyama R; Abe M; Kurikawa N; Kawamura S; Yamato M; Osumi J
Bioorg Med Chem Lett; 2009 Aug; 19(15):4151-8. PubMed ID: 19540759
[TBL] [Abstract][Full Text] [Related]
33. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
34. SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
Ramtohul YK; Black C; Chan CC; Crane S; Guay J; Guiral S; Huang Z; Oballa R; Xu LJ; Zhang L; Li CS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1593-7. PubMed ID: 20137926
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of stearoyl-CoA desaturase1 activates AMPK and exhibits beneficial lipid metabolic effects in vitro.
Kim E; Lee JH; Ntambi JM; Hyun CK
Eur J Pharmacol; 2011 Dec; 672(1-3):38-44. PubMed ID: 21970804
[TBL] [Abstract][Full Text] [Related]
37. N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
Atkinson KA; Beretta EE; Brown JA; Castrodad M; Chen Y; Cosgrove JM; Du P; Litchfield J; Makowski M; Martin K; McLellan TJ; Neagu C; Perry DA; Piotrowski DW; Steppan CM; Trilles R
Bioorg Med Chem Lett; 2011 Mar; 21(6):1621-5. PubMed ID: 21324691
[TBL] [Abstract][Full Text] [Related]
38. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
Roongta UV; Pabalan JG; Wang X; Ryseck RP; Fargnoli J; Henley BJ; Yang WP; Zhu J; Madireddi MT; Lawrence RM; Wong TW; Rupnow BA
Mol Cancer Res; 2011 Nov; 9(11):1551-61. PubMed ID: 21954435
[TBL] [Abstract][Full Text] [Related]
39. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.
Tawa P; Falgueyret JP; Guiral S; Isabel E; Powell DA; Zuck P; Skorey K
J Biomol Screen; 2011 Jun; 16(5):506-17. PubMed ID: 21406617
[TBL] [Abstract][Full Text] [Related]
40. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease.
Zhang Z; Dales NA; Winther MD
J Med Chem; 2014 Jun; 57(12):5039-56. PubMed ID: 24295027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
